Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal
NCT ID: NCT06872593
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
54 participants
INTERVENTIONAL
2025-07-14
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Excessive daytime sleepiness (EDS) is a symptomatic condition resulting from too little or compromised sleep, caused by psycho-social stress (shiftwork, lifestyle) or medical conditions (obstructive sleep apnoea (OSA), narcolepsy). Driving with untreated EDS might lead to sleepy/drowsy driving and microsleep, which is considered to be one of the highest-ranking causes of road accidents. Sleepiness and its dangers on the wheel might subjectively not be registered by the affected drivers. Also, subjective sleepiness might not correlate with somnological measurements that are also crucial for legally determining the fitness to drive (FTD).
There exists a variety of partially complementary tools to evaluate the extent of EDS. Mean sleep latency obtained in the maintenance of wakefulness test (MWT) is widely, but not uniformly, considered to be one of the most objective measures to evaluate EDS, especially in the context of driving performance. However, there is inconsistent or insufficient evidence for MWTs to reliably predict the FTD in general, potentially as its result might be strongly influenced by motivation. Moreover, patients might not relate low mean MWT-latencies to their own and other's risks in traffic.
A need for improved tools to measure EDS was formulated. It remains open, whether the MWT should be replaced or complemented by, for example, future road-side metabolomics-tests detecting sleepiness in traffic or whether the MWT should be adapted to better convey a.) the risks of EDS in traffic and b.) its meaning for the determination of the FTD.
With this need in mind the investigators proposed furnishing the maintenance of wakefulness test with improved ecological validity to provide an improved tool for the assessment of the effect of excessive daytime sleepiness on the fitness to drive: recently published results from an exploratory feasibility study suggested it to be well possible to transfer the MWT-paradigm to a driving simulator (DS) with high user acceptance. The published result's implication and relevance was well received: the new test, DS-MWT, might complement somnological MWTs in pneumology and neurology. I might provide a naturalistic and relatable tool to determine EDS in traffic medicine, who is institutionally responsible for determining the FTD. This is also desirable, because prohibitively high cost - in time, money and instrumentation - often prevent a standard MWT in standard care of sleep-related medical conditions. Potentially, the use of the DS-MWT might help reduce the number of preventable road fatalities by more often identifying sleepy individuals before they get behind the wheel.
However, for this goal to be achieve, it remains to be evaluated whether the latencies obtained in classical or simulation conditions are comparable and whether obtained latencies actually reflect other clinical parameters of EDS relating to underlying medical conditions, such as for example OSA. This represents a significant gap of evidence for both medical experts in pneumology and traffic medicine, but also for affected drivers. This gap will be filled by systematically comparing classical and simulation-based MWTs by means of their resulting latencies. In a within-study setup of 36 highly adherent OSA-patients, experiments will be related to a main medical comparator, a ≥7-day continuous positive airway pressure (CPAP)-withdrawal (W) and subsequent -resumption or continuation (C), respectively. There will be a control group of 18 healthy participants for comparison.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute and Long-term Effects of CPAP in OSA
NCT06277115
Upper Airway Reeducation in Moderate Obstructive Sleep Apnea Syndrome
NCT05911971
Video Consultation in CPAP for Patients With Obstructive Sleep Apnea
NCT04563169
Randomized-controlled Trial (RCT) on CPAP-withdrawal and Microvascular Function in OSA
NCT01797653
Upper Airway Stimulation Versus Continuous Positive Airway Pressure
NCT03756805
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OSA - W(first) + MD
allocated OSA-participants will perform test sequence M -\> D first after 7d CPAP-withdrawal, then after ≥7d CPAP.
CPAP-withdrawal
7-day-long CPAP-withdrawal
Test Sequence
Test Sequence M or D as specified in arm description
OSA - W(first) + DM
allocated OSA-participants will perform test sequence D -\> M first after 7d CPAP-withdrawal, then after ≥7d CPAP.
CPAP-withdrawal
7-day-long CPAP-withdrawal
Test Sequence
Test Sequence M or D as specified in arm description
OSA - C(first) + MD
allocated OSA-participants will perform test sequence M -\> D first after ≥7d CPAP, then after 7d CPAP-withdrawal.
CPAP-withdrawal
7-day-long CPAP-withdrawal
Test Sequence
Test Sequence M or D as specified in arm description
OSA - C(first) + DM
allocated OSA-participants will perform test sequence D-\> M first after ≥7d CPAP, then after 7d CPAP-withdrawal.
CPAP-withdrawal
7-day-long CPAP-withdrawal
Test Sequence
Test Sequence M or D as specified in arm description
Healthy control MD - DM
healthy participants will perform test sequence M -\> D first , then D -\> M
Test Sequence
Test Sequence M or D as specified in arm description
Healthy control DM - MD
healthy participants will perform test sequence D -\> M first , then M -\> D.
Test Sequence
Test Sequence M or D as specified in arm description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPAP-withdrawal
7-day-long CPAP-withdrawal
Test Sequence
Test Sequence M or D as specified in arm description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Inclusion criteria (healthy comparison croup): adult drivers, no declared psychiatric disorders, no declared sleep-related diagnosis, at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)
Exclusion criteria (for both groups): sensibility to motion sickness (kinetosis, dizziness, etc. in 5 min screening drive), professional drivers (if working during the study period), inability to understand the study procedure for linguistic or cognitive reasons.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Zürich
OTHER
Stefan Lakämper
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefan Lakämper
Dr. rer. nat. , Head Research & Research Development, Division of TRaffic Medicine, Institute for Forensic Medicine, University of Zurich
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Lakämper, Dr. rer. nat.
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Esther I Schwarz, PD, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Kristina Keller, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Traffic Medicine, Institute of Forensic Medicine, University of Zurich
Zurich, ZRH, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pisteljic M, Keller K, Lakamper S. Capturing sleep accidents in driving simulation as a promising tool to assess excessive daytime sleepiness with high ecological validity-a pilot study. Sleep. 2024 Aug 14;47(8):zsae110. doi: 10.1093/sleep/zsae110. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
Swiss National Clinical Trial Prortall (SNCTP) Registration of DS-MWT2
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DS-MWT2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.